Dementia: World Health Organization (WHO). World Health Organization. 2021. Available from: https://www.who.int/news-room/fact-sheets/detail/dementia. Accessed 15 Jan 2023.
Jessen F, Amariglio RE, Buckley RF, van der Flier WM, Han Y, Molinuevo JL, et al. The characterisation of subjective cognitive decline. Lancet Neurol. 2020;19:271–8. Lancet Publishing.
Article PubMed PubMed Central Google Scholar
Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3):183–94.
Article CAS PubMed Google Scholar
Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Budd Haeberlein S, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease HHS public access author manuscript. Alzheimers Dement. 2018;14(4):535–62. https://doi.org/10.1016/j.jalz.2018.02.018. Cited 2022 Dec 6.
Article PubMed PubMed Central Google Scholar
Wimo A, Seeher K, Cataldi R, Cyhlarova E, Dielemann JL, Frisell O, et al. The worldwide costs of dementia in 2019. Alzheimers Dement. 2023;19:2865–73.
Cummings J, Lee G, Nahed P, Kambar M, Zhong K, Fonseca J. Alzheimer’s disease drug development pipeline: 2022. Alzheimers Dement. 2022;8(1):e12295.
Hansson O, Edelmayer RM, Boxer AL, Carrillo MC, Mielke MM, Rabinovici GD, et al. The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease. Alzheimers Dement. 2022;18(12):2669–86. https://doi.org/10.1002/alz.12756.
Gonzalez-Ortiz F, Turton M, Kac PR, Smirnov D, Premi E, Ghidoni R, et al. Brain-derived tau: a novel blood-based biomarker for Alzheimer’s disease-type neurodegeneration Plasma BD-tau as an AD degeneration marker. Brain. 2023;146(3):1152–65.
Tochel C, Smith M, Baldwin H, Gustavsson A, Ly A, Bexelius C, et al. What outcomes are important to patients with mild cognitive impairment or Alzheimer’s disease, their caregivers, and health-care professionals? A systematic review. Alzheimers Dement (Amst). 2019;1(11):231–47.
Karimi M, Brazier J. Health, health-related quality of life, and quality of life: what is the difference? Pharmacoeconomics. 2016;34(7):645–9.
Brooks R. EuroQol: the current state of play. Health Policy (New York). 1996;37(1):53–72.
Horsman J, Furlong W, Feeny D, Torrance G. The Health Utilities Index (HUI ® ): concepts, measurement properties and applications. Health Qual Life Outcomes. 2003;1:54.
Article PubMed PubMed Central Google Scholar
Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21(2):271–92.
Mulhern B, Rowen D, Brazier J, Smith S, Romeo R, Tait R, et al. Development of DEMQOL-U and DEMQOL-PROXY-U: Generation of preference-based indices from DEMQOL and DEMQOL-PROXY for use in economic evaluation. Health Technol Assess. 2013;17(5):v–xv.
Article CAS PubMed PubMed Central Google Scholar
Vergel YB, Sculpher M. Quality-adjusted life years. Pract Neurol. 2008;8(3):175–82.
Shearer J, Green C, Ritchie CW, Zajicek JP. Health state values for use in the economic evaluation of treatments for Alzheimer’s disease. Drugs Aging. 2012;29(1):31–43.
Landeiro F, Mughal S, Walsh K, Nye E, Morton J, Williams H, et al. Health-related quality of life in people with predementia Alzheimer’s disease, mild cognitive impairment or dementia measured with preference-based instruments: a systematic literature review. Alzheimers Res Ther. 2020;12(1):154.
Article PubMed PubMed Central Google Scholar
Gustavsson A, Raket LL, Lilja M, Rutten-Jacobs L, Fues Wahl H, Bagijn M, et al. Health utility in preclinical and prodromal Alzheimer’s disease for establishing the value of new disease-modifying treatments-EQ-5D data from the Swedish BioFINDER study. Alzheimers Dement. 2021;17(11):1832–42.
Mank A, Rijnhart JJ, van Maurik IS, Jönsson L, Handels R, Bakker ED, et al. A longitudinal study on quality of life along the spectrum of Alzheimer’s disease. Alzheimers Res Ther. 2022;14(1):132.
Article CAS PubMed PubMed Central Google Scholar
Heßmann P, Seeberg G, Reese JP, Dams J, Baum E, Müller MJ, et al. Health-related quality of life in patients with Alzheimer’s disease in different German health care settings. J Alzheimers Dis. 2016;51:545–61.
León-Salas B, Olazará J, Cruz-Orduñ I, Agü Era-Ortiz L, Dobato JL, Valentí-Soler M, et al. Quality of life (QoL) in community-dwelling and institutionalized Alzheimer’s disease (AD) patients. Arch Gerontol Geriatr. 2013;57(3):257–62.
Dufouil C, Dubois B, Vellas B, Pasquier F, Blanc F, Hugon J, et al. Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort. Alzheimers Res Ther. 2017;9(1):1–3.
Morris JC. Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeriatr. 1997;9(Suppl 1):173–6.
Folstein M, Folstein S, McHugh P. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiat Res. 1975;12:189–98.
Article CAS PubMed Google Scholar
De Medeiros K, Robert P, Gauthier S, Stella F, Politis A, Leoutsakos J, et al. The Neuropsychiatric Inventory-Clinician rating scale (NPI-C): reliability and validity of a revised assessment of neuropsychiatric symptoms in dementia. Int Psychogeriatr. 2010;22(6):984–94.
Article PubMed PubMed Central Google Scholar
Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9(3):179–86.
Article CAS PubMed Google Scholar
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th ed.). 4th ed. 1994.
Guy M, David D, Marshall F, Robert K, Donald P, Emanuel MS. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under auspices of the Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology. 1984;34:939–44.
Chevalier J, De Pouvourville G. Valuing EQ-5D using time trade-off in France. Eur J Health Econ. 2013;14(1):57–66.
Dufournet M, Moutet C, Achi S, Delphin-Combe F, Krolak-Salmon P, Dauphinot V, et al. Proposition of a corrected measure of the Lawton instrumental activities of daily living score. BMC Geriatr. 2021;21:1–10.
Zaidi S, Kat MG, De Jonghe JFM. Clinician and caregiver agreement on neuropsychiatric symptom severity: a study using the Neuropsychiatric Inventory - Clinician rating scale (NPI-C). Int Psychogeriatr. 2014;26(7):1139–45.
Königsberg A, Belau MH, Ascone L, Gallinat J, Kühn S, Jensen M, et al. Subjective cognitive decline is associated with health-related quality of life in the middle-aged to elderly population. J Alzheimers Dis. 2023;91:427–36.
Lee S, Ho CJ. The association between subjective cognitive decline and quality of life: a population-based study. J Clin Neurosci. 2022;1(98):60–5.
Jönsson L, Andreasen N, Kilander L, Soininen H, Waldemar G, Nygaard H. Patient-and proxy-reported utility in Alzheimer disease using the EuroQoL. Alzheimer Dis Assoc Disord. 2006;20(1):49–55.
Li L, Nguyen KH, Comans T, Scuffham P. Utility-based instruments for people with dementia: a systematic review and meta-regression analysis. Value Health. 2018;21(4):471–81.
Binnekade TT, Scherder EJA, Maier AB, Lobbezoo F, Overdorp EJ, Rhebergen D, et al. Pain in patients with different dementia subtypes, mild cognitive impairment, and subjective cognitive impairment. Pain Med. 2018;19(5):920–7.
Liu-Seifert H, Siemers E, Sundell K, Price K, Han B, Selzler K, et al. Cognitive and functional decline and their relationship in patients with mild Alzheimer’s dementia. J Alzheimers Dis. 2015;43(3):949–55.
Article CAS PubMed Google Scholar
Delva F, Auriacombe S, Letenneur L, Foubert-Samier A, Bredin A, Clementy A, et al. Natural history of functional decline in Alzheimer’s disease: a systematic review. J Alzheimers Dis. 2014;40(1):57–67.
Janssen N, Handels RL, Wimo A, Antikainen R, Laatikainen T, Soininen H, et al. Association between cognition, health related quality of life, and costs in a population at risk for cognitive decline. J Alzheimers Dis. 2022;89(2):623–32.
Article PubMed PubMed Central Google Scholar
Lyketsos CG, Carrillo MC, Michael Ryan J, Khachaturian AS, Trzepacz P, Amatniek J, et al. Neuropsychiatric symptoms in Alzheimer’s disease. Alzheimers Dement. 2011;7(5):532–9.
Article PubMed PubMed Central Google Scholar
Lanctôt KL, Amatniek J, Ancoli-Israel S, Arnold SE, Ballard C, Cohen-Mansfield J, et al. Neuropsychiatric signs and symptoms of Alzheimer’s disease: new treatment paradigms. Alzheimers Dement (N Y). 2017;3(3):440–9.
Comments (0)